Royalty Pharma (RPRX) Total Debt Growth (1y) (2020 - 2026)
Royalty Pharma (RPRX) Total Debt Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 103.99% |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 3.84% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.07% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Royalty Pharma | 25.78 Bn | 28.22 Bn | - | 22.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.57% |
| Dec 31, 2025 | 8.37% |
| Sep 30, 2025 | 17.59% |
| Jun 30, 2025 | 5.27% |
| Mar 31, 2025 | 24.08% |
| Dec 31, 2024 | 40.34% |
| Sep 30, 2024 | 24.08% |
| Jun 30, 2024 | 6.67% |
| Mar 31, 2024 | -24.39% |
| Dec 31, 2023 | -13.79% |
| Sep 30, 2023 | -24.38% |
| Jun 30, 2023 | -1.33% |
| Mar 31, 2023 | 12.51% |
| Dec 31, 2022 | -1.22% |
| Sep 30, 2022 | 12.46% |
| Jun 30, 2022 | 21.53% |
| Mar 31, 2022 | 21.71% |
| Dec 31, 2021 | 21.22% |
| Sep 30, 2021 | 24.05% |
| Jun 30, 2021 | 0.53% |